Transcranial Photobiomodulation With Patients With Parkinson's Disease

April 6, 2025 updated by: Hanan Hosny M Battesha, Al-Zaytoonah University of Jordan

Posture Stability and Functional Activity Changes After Transcranial Photobiomodulation for Patients With Parkinson's Disease: A Randomized Controlled Trial

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive and disabling disease with significative impact on quality of life. Since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. The aim of the study was to see how transcranial photobiomodulation (tPBM) helped patients with Parkinson's disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Jordan
      • Amaan, Jordan
        • Al Zaytoonah University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • idiopathic PD,
  • Hoehn & Yahr stage I-IV,
  • independent gait with or without technical assistance
  • stable parkinsonian medication for at least a month before the study star.

Exclusion Criteria:

  • comorbidities that affect balance or walking,
  • other neurological pathologies besides PD,
  • chronic diseases not medically controlled and participation in another physiotherapy program or sport activity during the intervention period or in the month before starting the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control group
Other: exercises training
balance exercises and others
Experimental: study group
Device: transcranial photobiomodulation
Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
posture stability
Time Frame: 8 weeks
The Biodex Balance System (Biodex Medical Systems Inc, USA) Will be used to assess the limit of stability (overall, forward and backward) pre- and post-treatment.
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
functional activity
Time Frame: 8 weeks
The modified Parkinson activity scale (mPAS) consist of 14 items arranged on to three domains: chair transfer (2 items), gait akinesia (6 items) and bed mobility (6 items)
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Zaytoonah University of Jordan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2024

Primary Completion (Actual)

March 20, 2025

Study Completion (Actual)

April 3, 2025

Study Registration Dates

First Submitted

December 5, 2024

First Submitted That Met QC Criteria

December 10, 2024

First Posted (Actual)

December 11, 2024

Study Record Updates

Last Update Posted (Actual)

April 8, 2025

Last Update Submitted That Met QC Criteria

April 6, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PD , LASER

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on transcranial photobiomodulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe